Page 4 - Mankind Pharma

Stocks to watch on March 26: UltraTech, Mankind Pharma, RIL, RVNL, Lupin

Stocks to Watch on March 26, 2024: Reliance Industries acquired a 100 per cent stake in MSKVY Nineteenth Solar SPV and MSKVY Twenty-second Solar SPV from MSEB Solar Agro Power

AstraZeneca, Mankind Pharma partner for distribution of asthma medication

Mankind Pharma, a pharmaceutical company in India, boasts a vast distribution network with over 16,000 field personnel and 13,000 stockists

AstraZeneca, Mankind Pharma sign pact to distribute asthma medicine

AstraZeneca Pharma India Ltd and Mankind Pharma Ltd on Monday said they have entered into an agreement for exclusive distribution of the Symbicort brand, an asthma medicine, in India. Symbicort is owned by AstraZeneca, which will retain the intellectual property rights and will continue to be the marketing authorisation holder (MAH) and import license after the agreement, a joint statement shared on BSE by AstraZeneca Pharma India said. "The partnership with Mankind Pharma presents an opportunity to accelerate access and maximise the potential of our asthma drug as well as the turbuhaler which is a simple device, efficient in consistently delivering a higher proportion of respirable particles than the other devices," AstraZeneca India Managing Director and Country President Sanjeev Panchal said. Mankind Pharma has a distribution network, including close to 16,000 field forces and more than 13,000 stockists, across India providing access to quality pharmaceuticals across the country,

Promoters of Mankind Pharma divest 1.6% stake worth Rs 1,367 crore

Mankind Pharma promoters on Thursday divested a 1.62 per cent stake in the company for Rs 1,367 crore through open market transactions. According to the block deal data available with the NSE, promoters Sheetal Arora, Puja Juneja, and Arjun Juneja offloaded a total of 64,89,534 shares in two tranches each, representing a 1.62 per cent stake in Mankind Pharma, on the NSE. The shares were disposed of at an average price of Rs 2,107.35 apiece, taking the combined deal value to Rs 1,367.57 crore. Through the latest transaction, the combined shareholding of promoter and promoter group entities have declined to 74.88 per cent stake from 76.50 per cent stakeholding (as of December quarter) in Mankind Pharma. As per market regulations, all listed companies must maintain an minimum public shareholding of 25 per cent, while newly-listed firms are given three years to meet the requirement of 25 per cent public float. Accordingly, after the stake sale, the company has complied with the norms

Mankind Pharma promoters to divest 1.62% stake to comply with Sebi norms

The current aggregate promoter and promoter group shareholding as on February 7 is 76.50 per cent of the total paid-up equity share capital of the company

Mankind Pharma Q3 results: PAT up 55% on strong domestic performance

Mankind's revenue from operations rose to Rs 2,607 crore in Q3 FY24, a 25 per cent Y-o-Y rise in revenue from operations from Rs 2,128 crore in Q2 FY23

Stock of this pharma company has nearly doubled against its issue price

Mankind hit record high of Rs 2,132.10, rallied 8% in intra-day trade and zoomed 97% against its issue price of Rs 1,080 per share.

Battery recycling startup BatX Energies raises $5 mn in early stage funding

Battery recycling startup BatX Energies on Tuesday said it raised USD 5 million (over Rs 40 crore) in an early stage funding round led by Zephyr Peacock. Lets Venture as well as existing investors JITO Angel Network and family offices of Mankind Pharma, Excel Industries, and BluSmart also participated in the pre-Series A funding round, BatX Energies said in a statement. The infusion of fresh funds will help scale up recycled battery-grade lithium, nickel and cobalt production and establish a secured nationwide reverse logistics network for sourcing, it added. "Through strategic allocation of these funds, we're poised to power our vision of sustainable energy solutions. We're directing resources towards pioneering R&D initiatives, elevating the production of superior battery-grade materials," BatX Energies Co-founder & CTO Vikrant Singh said. He further said, "This investment propels our mission to expand globally and establish micro facilities nationwide, fostering a future ...

3 PE firms offload 7.9% in Mankind; Motisons Jewellers IPO to open Dec 18

The deals took place at around Rs 1,832 apiece. Shares of Mankind fell 3.6 per cent to close at Rs 1,849

Stocks to Watch: Sun Pharma, Infosys, Dixon, DLF, Mankind Pharma, SpiceJet

Stocks to watch on December 12, 2023: Sun Pharma has increased its offer price for acquiring remaining shares of Taro Pharma to $43 per share in cash, compared to $38 before

Mankind Pharma surges 5%, Flair Writing sets price band of Rs 288-304

Besides Flair, the company's products are sold under brands such as Hauser, Pierre Cardin and Zoox

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

The delayed season not only affected anti-infectives but also related sub-therapies such as respiratory, cough and cold, gastro, and vitamins, says Juneja

Street signs: Bulls charge ahead, IPO stars shine bright, and more

Shares of Mankind Pharma, SBFC Finance, and Fusion Micro Finance are likely to attract attention as the lock-in periods related to their initial public offerings (IPOs) come to an end

Stocks to Watch: Bharti Airtel, L&T, Tata Motors, Ethos, Blue Jet, Mankind

Stocks to watch on November 1, 2023: Bank of Baroda's head of digital lending, Akhil Handa, a techie closely associated with building the mobile banking application 'bob World', has quit

Mankind Pharma Q2 results: Consolidated net profit rises 21% to Rs 511 cr

Mankind Pharma on Tuesday said its consolidated net profit increased by 21 per cent to Rs 511 crore for the second quarter ended September 30, 2023, on the back of robust performance across segments. The company had reported a net profit of Rs 422 crore in the July-September period of the last fiscal. Revenue from operations rose to Rs 2,708 crore in the period under review from Rs 2,425 crore in the year-ago period, Mankind Pharma said in a regulatory filing. "The past strategic choices in various aspects of our business are showing success, and we are confident in our ability to consistently surpass the industry growth in future," Mankind Pharma Vice Chairman & Managing Director Rajeev Juneja said. Shares of Mankind Pharma on Tuesday ended 0.7 per cent lower at Rs 1,741.10 apiece on the BSE.

ChrysCapital bullish on future of tech, pharma and financial services

The firm worked closely with ManKind Pharma and ran an internal cost reduction program which saved them close to Rs 100 crores

RR Kabel IPO subscribed 25% on day 1, price band at Rs 983 to Rs 1,035

The fresh issue component of the IPO is only Rs 180 crore and the remaining is secondary share sale by promoters and TPG

Mankind Pharma PAT up 66% in Q1 to Rs 494 crore on revenue growth

Juneja also highlighted a 43 per cent YoY increase in Ebitda as a positive outcome of the company's previous initiatives to improve profitability

Stocks to Watch today, July 5: LTIMindtree, Bandhan Bk, Lupin, Adani Power

Stocks to Watch on Wednesday, July 5: LTIMindtree will replace HDFC in the benchmark Nifty50 index, while LIC Housing Finance will likely replace it in the Nifty Financial Services index

Mankind Pharma's success boosts hopes of more consumer IPOs in India

The company, which raised Rs 4,330 crore ($528 million) in India's second-largest new share sale this year, has seen its shares jump 57% in almost two months, drawing a rush of buy calls from analysts